TrialBMC cancer2015

Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT).

Richard D Carvajal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.